👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

Federal prosecutors open criminal probe of opioid makers, distributors: WSJ

Published 11/26/2019, 02:16 PM
© Reuters. A person holds pharmaceutical tablets and capsules in illustration picture in Ljubljana
TEVA
-
MCK
-
COR
-
JNJ
-
TEVA
-
AMRX
-
MNKKQ
-

(Reuters) - Federal prosecutors have opened a criminal investigation into whether pharmaceutical companies intentionally allowed opioid painkillers to flood communities, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.

At least six companies have received grand-jury subpoenas from the U.S. attorney's office in the Eastern District of New York - Teva Pharmaceutical (NYSE:TEVA) Industries Ltd (TA:TEVA), Mallinckrodt Plc (N:MNK), Johnson & Johnson (N:JNJ) and Amneal Pharmaceuticals Inc (N:AMRX) and distributors AmerisourceBergen Corp (N:ABC) and McKesson Corp (N:MCK), the Journal reported.

Shares of Amneal, Teva and McKesson fell between 3% and 7%, while AmerisourceBergen and Mallinckrodt were down marginally.

The subpoenas were in connection with a Brooklyn federal probe, the Journal reported.

A spokesman for the Brooklyn U.S. attorney's office declined to comment.

The probe is in early stages and prosecutors are expected to send subpoenas to other companies in the coming months, the report said, citing one of the sources.

The companies did not immediately respond to Reuters' requests for comment.

Teva, J&J, Amneal and Mallinckrodt disclosed in recent regulatory filings that they received subpoenas from the U.S. attorney's office in Brooklyn, which the companies generally described as regarding their anti-diversion policies and procedures and distribution of opioid medications.

The companies said it was part of a broader investigation into manufacturers’ and distributors’ monitoring programs and reporting under the Controlled Substances Act.

Teva, Mallinckrodt and J&J also said they had received subpoenas from the New York State Department of Financial Services as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums.

Opioid manufacturers, distributors and pharmacy chains have been defending themselves against thousands of lawsuits by state attorneys general, local governments and class actions accusing them of fueling an addiction crisis.

Opioids have contributed to more than 400,000 deaths since 1997, according to government statistics.

© Reuters. A person holds pharmaceutical tablets and capsules in illustration picture in Ljubljana

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.